Transfoveal Micropulse Laser for Center Involving Diabetic Macular Edema

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Kiungo kimehifadhiwa kwenye clipboard

HaliImekamilika

Wadhamini

Cairo University

JARIBIO LA KLINIKI: NCT04359771

BioSeek: nct04359771

Maneno muhimu

tambazi

Kikemikali

Anti-vascular endothelial growth factor (VEGF) therapy is currently the mainstay of treatment for diabetic macular edema (DME). One of the main obstacles of anti-VEGF therapy is the need of repeated injections, which carries both economic and compliance problems to the patients.there is a growing evidence that recognises the effectiveness of the use of micropulse laser (MPL) in treatment of DME. with MPL, it is possible to deliver a subthreshold laser that is above the threshold of biochemical effect but below the threshold of a visible, destructive lesion thereby preventing collateral damage.The MPL technique is available at near - infrared 810 nm diode laser (diode MPL) and at 577 nm (yellow MPL). The current study was conducted in order to compare the efficacy of both MPL techniques in the treatment of center involving DME.

Maelezo

This was a prospective randomized comparative study that included 30 eyes of 15 patients with bilateral DME. The patients were recruited from the Retina Clinic at Kasr Al Ainy Hospital, Cairo University. The study's protocol was reviewed and approved by board of the ophthalmology department, Cairo University, and was in concordance with the tents of Declaration of Helsinki. Eligible patients were informed about the study's objectives, methodology, risks and benefits. A written informed consent was obtained from every patient included in this study.Preliminary examination was in the form of slit-lamp examination, fundus examination, intra ocular pressure measurement, and best corrected visual acuity (BCVA) measurement. A spectral domain optical coherence tomogram (OCT) scan was performed to all patients before treatment to measure the central retinal thickness (CRT). The eyes were randomized into two groups; one eye (right eye) of each patient was treated with 577-nm yellow MPL and the other eye (left eye) of the same patient with Infrared 810-nm diode MPL. Changes in the BCVA and CRT were measured after treatment at 1 and 3 months of follow up.

Tarehe

Imethibitishwa Mwisho:	04/30/2020
Iliyowasilishwa Kwanza:	04/20/2020
Uandikishaji uliokadiriwa Uliwasilishwa:	04/21/2020
Iliyotumwa Kwanza:	04/23/2020
Sasisho la Mwisho Liliwasilishwa:	05/14/2020
Sasisho la Mwisho Lilichapishwa:	05/31/2020
Tarehe ya matokeo ya kwanza yaliyowasilishwa:	05/02/2020
Tarehe ya matokeo ya kwanza ya QC yaliyowasilishwa:	05/02/2020
Tarehe ya matokeo ya kwanza kuchapishwa:	05/17/2020
Tarehe halisi ya kuanza kwa masomo:	01/21/2018
Tarehe ya Kukamilisha Msingi iliyokadiriwa:	09/24/2018
Tarehe ya Kukamilisha Utafiti:	09/24/2018

Hali au ugonjwa

Diabetic Retinopathy

Macula Edema

Uingiliaji / matibabu

Device: Yellow MPL

Device: Diode MPL

Awamu

Awamu 4

Vikundi vya Arm

Mkono	Uingiliaji / matibabu
Active Comparator: Yellow MPL	Device: Yellow MPL applying 577-nm yellow laser in a micro-pulse mode over the macular area including the fovea
Active Comparator: Diode MPL	Device: Diode MPL applying 810-nm infra-red diode laser in a micro-pulse mode over the macular area including the fovea

Vigezo vya Kustahiki

Zama zinazostahiki Kujifunza	20 Years Kwa 20 Years
Jinsia Inastahiki Kujifunza	All
Hupokea Wajitolea wa Afya	Ndio
Vigezo	Inclusion Criteria: - bilateral diabetic macular edema - center involving confirmed by Optical coherence tomogram (OCT) Exclusion Criteria: - any non-diabetic macular edema - significant media opacities - previous laser treatment, any intraocular surgery within the past 6 months - previous intravitreal injections of any drug within the past 6 months

Matokeo

Hatua za Matokeo ya Msingi

1. Change in Central Retinal Thickness (CRT) [baseline, at 1 month and 3 months after the intervention]

detecting changes in the thickness of the center of the macula

2. Change in the Best Corrected Visual Acuity (BCVA) [baseline, at 1 month and 3 months after the intervention]

detecting changes in the the best corrected visual acuity in logMAR. A LogMAR chart comprises rows of letters and is used by ophthalmologists, optometrists and vision scientists to estimate visual acuity. This chart was developed at the National Vision Research Institute of Australia in 1976, and is designed to enable a more accurate estimate of acuity than do other charts (e.g., the Snellen chart). For this reason, the LogMAR chart is recommended, particularly in a research setting. A Snellen score of 6/6 (20/20), indicating that an observer can resolve details as small as 1 minute of visual angle, corresponds to a LogMAR of 0 (since the base-10 logarithm of 1 is 0); a Snellen score of 6/12 (20/40), indicating an observer can resolve details as small as 2 minutes of visual angle, corresponds to a LogMAR of 0.3 (since the base-10 logarithm of 2 is near-approximately 0.3), and so on.Therefore, a higher logMAR scores mean a worse outcome.